BIO:ON Insight EN #8 · Jul 12, 2026 · Oral Obesity Drug · ADC · AI Drug Discovery

The drug works.
Now comes the fight over insurance, channels and trust

An obesity pill held back by insurers, a cancer drug that finally won in small-cell lung cancer, and an AI startup that can't run trials on its own. This week's three stories, read for your career.

Reading this week's three stories, one question kept coming up: does a good drug always reach patients? Lilly's oral obesity pill is selling slowly, not because of the drug but because insurers haven't added it to their lists. GSK and Hansoh's ADC won a historic Phase 3, but now the commercial race begins. And even a billion-dollar AI startup can't finish a drug without Big Pharma's clinical network. Winning on science isn't the end. There's always a second fight.

— Editor · MSc Biotechnology & Pharmaceutical Management

🔤 Word of the Week

ADC (Antibody-Drug Conjugate)

The technology behind this week's GSK and Hansoh small-cell lung cancer win (Story 2)

An ADC links two things into one cancer drug: an antibody that finds cancer cells precisely (the guided missile) and a powerful cytotoxic payload that kills them (the warhead). The antibody latches onto a specific protein on the cancer cell's surface, and the toxin is released inside, destroying mainly cancer cells. GSK and Hansoh's risvutatug rezetecan targets B7-H3, a protein overexpressed in many cancers, and this is the first Phase 3 survival data for a B7-H3 drug.

💡 Analogy: Traditional chemotherapy is a bomber: it damages healthy cells near the target too. An ADC is a smart missile carrying the cancer cell's address (the antibody) and exploding only at that house. The promise is stronger anti-cancer effect with less hair loss, nausea and immune suppression.

Traditional chemotherapy

Cytotoxic drugs go into the bloodstream and attack any fast-dividing cells. They kill cancer cells but also harm hair, gut and immune cells, which is behind hair loss, nausea and low immunity.

ADC (antibody-drug conjugate)

The antibody finds the cancer cell, and the toxin is released inside it. Healthy tissue sees much less toxin, so side effects improve. GSK and Hansoh's ADC used this approach to extend survival in Phase 3 in small-cell lung cancer, where five-year survival is only around 7%.

📰 This Week's Top 3 Stories

STORY 1 · ORAL OBESITY DRUG · MARKET ACCESS

Lilly's Oral Obesity Pill Foundayo Gets Off to a Slow Start as Insurance Coverage Lags

Fierce Pharma · Eli Lilly (NYSE: LLY) | Jul 10, 2026

Key Facts

According to IQVIA prescription data, Eli Lilly's newly launched oral obesity drug Foundayo is being prescribed more slowly than Novo Nordisk's competing product. The reason isn't efficacy: it's delays in getting on pharmacy benefit manager (PBM) formularies. In the US, the three big PBMs — Express Scripts, CVS Caremark and OptumRx — manage about 80% of prescriptions. Without broad formulary coverage, patients face full cash prices and doctors hesitate to prescribe. It's a product that could open the "needle-free obesity drug" era, but without the insurance channel, the prescriptions don't come.

Plain-English Breakdown 🧩

US prescriptions move from doctor to pharmacy to PBM. A drug has to be on a PBM's list for patients to get the insured price; if it isn't, patients pay everything themselves, and prescriptions dry up. A good drug that loses out on formularies can lose the market to a more ordinary rival. That's where Foundayo is right now.

🌍 Global Lens

PBMs are a very American problem. In the UK, Europe, Korea or Japan, a drug's reach depends on national price negotiations and health technology assessment instead, where the question is cost-effectiveness rather than rebates. That's a useful contrast: the same pill can win in one system and stall in another for completely different reasons.

Why it matters for your career: This is the day-to-day work of market access teams, and in the US it's increasingly where launches are won or lost.

📌 Lilly's oral obesity drug Foundayo is trailing its rival in first-month prescriptions because of PBM coverage delays — a fight over channels, not the drug. — Fierce Pharma summary

STORY 2 · ONCOLOGY · ADC

GSK and Hansoh's B7-H3 ADC Extends Survival in Small-Cell Lung Cancer Phase 3, a First for the Target

Fierce Biotech · GSK (NYSE: GSK) × Hansoh Pharmaceutical | Jul 10, 2026

Key Facts

GSK and Hansoh Pharmaceutical's co-developed ADC risvutatug rezetecan met its primary survival endpoint in a Phase 3 trial in advanced small-cell lung cancer (SCLC). It's the first ADC targeting B7-H3 to show a survival benefit in Phase 3. SCLC has a five-year survival rate of about 7% and very few treatment options, and that unmet need is the strongest case for the drug. B7-H3 is overexpressed in many other cancers too, which gives it blockbuster potential through new indications.

Plain-English Breakdown 🧩

SCLC often responds to chemotherapy at first but comes back quickly, with few options afterwards. The ADC uses an antibody to find cancer cells covered in B7-H3 and drops its toxin precisely. A smart missile got through a line the old bombers never could. Phase 3 survival data is the strongest evidence regulators like the FDA and EMA ask for, so it's the direct basis for a filing.

🌍 Global Lens

Hansoh is Chinese, and this drug is another China-born ADC that became a global asset through a licence to Western pharma. Small-cell lung cancer is common wherever smoking rates are high, including much of Asia and Eastern Europe, so a survival benefit has wide reach. Every oncology BD team is watching the flow of ADC deals out of China.

Why it matters for your career: Survival wins trigger filings, launch planning and indication expansion trials, which means more work for clinical, regulatory and medical teams.

📌 GSK and Hansoh's ADC extended survival in a small-cell lung cancer Phase 3 — the first win for a B7-H3 ADC. The commercial race starts now. — Fierce Biotech summary

STORY 3 · AI DRUG DISCOVERY

Xaira Therapeutics Comes Out of Stealth and Goes Looking for Big Pharma Partners

BioSpace · company briefing · Xaira Therapeutics (private) | Jul 8, 2026

Key Facts

Silicon Valley AI drug discovery startup Xaira Therapeutics made its first public move since launch, saying it is actively seeking co-development partnerships with Big Pharma. Xaira raised more than $1 billion when it was founded in 2024, one of the largest starting war chests for any AI drug startup. It uses generative AI to automate everything from protein structure prediction to candidate design. But even the best AI platform can't get a drug to patients without the infrastructure to run Phase 1–3 trials: patient recruitment, clinical networks and regulatory experience. Hence the knock on Big Pharma's door.

Plain-English Breakdown 🧩

An AI company making a drug has two steps: (1) designing which molecule will act on which protein, and (2) testing it in people. AI can transform step one, but step two still needs a decade of human clinical infrastructure. However good Xaira's AI is, its drugs can't reach the market without a clinical network, and that dependence is a limit every AI drug startup shares.

🌍 Global Lens

This is Silicon Valley money running into an old truth: clinical trials still run through hospitals, regulators and patient networks all over the world. That's why Big Pharma, with its global trial infrastructure, keeps real bargaining power over even the best-funded AI startups. AI biotechs in London, Boston and Shanghai are all knocking on the same doors.

Why it matters for your career: AI biotechs need BD and alliance people who can sell a platform to partners and structure deals, and it's one of the less obvious ways into the sector.

📌 Xaira, the AI drug startup with more than $1B in funding, has gone public with a search for Big Pharma partners — even the best AI can't make a drug alone without a clinical network. — BioSpace / company briefing summary

🔬 This Week's Deep Dive

Deep Dive · Three Gates Every Drug Must Pass

The drug is done —
now come insurance, commercialisation and clinical networks

① Three things a drug must get past to reach patients

This week's stories show three companies each fighting their second battle. Foundayo won in the clinic but got stuck in the PBM channel. GSK and Hansoh's ADC won Phase 3, and now the commercial race begins. Xaira has top-tier AI but no clinical network, so it's knocking on Big Pharma's door. "The science won" is only half the story in drug development. Insurance, channels and partnerships are waiting outside the lab.

② Three gates, compared

Lilly (channel)	GSK × Hansoh (clinical)	Xaira (AI)
Where It Stands
Launched · negotiating PBM coverage	Phase 3 survival endpoint met	Looking for partners
Key Challenge
Getting onto PBM formularies	FDA filing and commercialisation	Securing a clinical network
Main Risk
Rival (Novo) gets there first	Fierce competition among ADCs	Unfavourable partnership terms

③ Why the distinction matters — every gate has its own jobs

Each gate creates demand for different specialists. The PBM fight needs market access and reimbursement experts. Commercialising a Phase 3 winner needs medical affairs, regulatory and marketing. AI partnerships need BD and clinical strategy people to make the deals. Being good at science alone won't get a drug through these gates, and that's why understanding what happens after research matters so much.

④ Career takeaway: learn the language after the lab

✓ Skill to build

The thread through all three stories is the same: the value of a drug is decided partly outside the lab. Try reading clinical data the way a payer, a partner or a regulator would. Ask "how would this look to an insurer?" or "what would a partner want in return?" That habit is what market access, medical affairs, BD and RA teams use every day, and it will make you sound like someone who already works in the industry.

⚠ Trap

Believing that a good drug will always sell. Foundayo shows that even an innovative drug won't be prescribed without insurance coverage, and an AI-designed candidate won't reach patients without a clinical partner. Scientific excellence alone doesn't decide a drug's value; look at market entry strategy, channels and partnerships too.

💡 Editor's Insight

What stayed with me this week was the feeling that the science has answered, but the world isn't ready yet. When you first get into biotech, it's easy to think passing Phase 3 is the finish line. But if you look at a drug's journey from lab to patient, clinical data is roughly the halfway point. The people who understand the other half — the language of insurance, channels and partnerships — are the ones who'll create real value in this industry. See you next issue. 🙏

📊 Numbers of the Week

$1B+

Xaira Therapeutics' total funding

One of the biggest AI drug discovery startups, which stayed largely in stealth from its 2024 founding until now.

~80%

Share of US prescriptions managed by the three big PBMs

Express Scripts, CVS Caremark and OptumRx. Without their coverage, even an FDA-approved drug struggles to reach patients.

~7%

Five-year survival in small-cell lung cancer

With current treatments, one of the worst prognoses in oncology. A Phase 3 survival win for the GSK × Hansoh ADC could start to change that.

📈 3 Stocks That Moved This Week

Direction and catalyst, sketched — not exact prices. Check a real chart for that.

Eli Lilly

NYSE: LLY

▽ Down

Reports that early Foundayo prescriptions were lower than expected weighed on shares, with PBM coverage delays blamed. (Directional sketch.)

GSK

NYSE: GSK

▲ Strong

The Hansoh-partnered ADC hitting its survival endpoint in SCLC boosted confidence in GSK's oncology pipeline, and the first B7-H3 Phase 3 win carried historic weight. Hiring signal: a filing and launch ahead usually means new oncology medical affairs and launch roles. (Directional sketch.)

Novo Nordisk

NYSE: NVO

▲ Slightly up

Foundayo's slow start was read as good for Novo's injectables (Ozempic, Wegovy), since the shift to oral obesity drugs may take longer than expected. (Directional sketch.)

🔎 Why this pattern

This week's reactions show the fight after the science. GSK's Phase 3 win brought an immediate rise, while Foundayo hit the PBM channel wall and slipped. The market weighs "can this actually sell?" as coldly as it weighs trial data. (All directional sketches — check a real chart for exact prices.)

🎯 Roles to Watch This Week

Teams worth watching based on this issue's news — not live job postings, so check each company's careers page for what's actually open.

Eli Lilly — Market Access / Payer Relations

Why now: winning PBM coverage for Foundayo is now the main lever for growth. Look under "Market Access," "Payer Relations" or "Trade."

GSK — Oncology Medical Affairs / Regulatory

Why now: a Phase 3 survival win in SCLC means a filing to prepare and oncologists to brief. Look under "Oncology Medical Affairs" or "Regulatory Affairs."

Xaira Therapeutics — Business Development / Alliance Management

Why now: a company actively looking for Big Pharma partners needs people who can build and manage those deals. Look for BD or partnerships roles on Xaira's careers page.

🗓️ Dates to Watch

When / Event	Why It Matters
H2 2026 (expected) Eli Lilly — Foundayo coverage decisions from the big PBMs	Coverage from Express Scripts, CVS Caremark and OptumRx is the key to growth; without it, Lilly stays behind Novo's injectables.
H2 2026 – 2027 (expected) GSK × Hansoh — risvutatug rezetecan FDA filing timeline	A BLA usually follows Phase 3 survival data within 6–12 months; Breakthrough Therapy designation is possible for the first B7-H3 ADC in SCLC.
H2 2026 (expected) Xaira Therapeutics — first Big Pharma partnership	The size and quality of the first deal will test how much confidence partners have in Xaira's platform.

When / Event

Why It Matters

H2 2026 (expected)

Eli Lilly — Foundayo coverage decisions from the big PBMs

Coverage from Express Scripts, CVS Caremark and OptumRx is the key to growth; without it, Lilly stays behind Novo's injectables.

H2 2026 – 2027 (expected)

GSK × Hansoh — risvutatug rezetecan FDA filing timeline

A BLA usually follows Phase 3 survival data within 6–12 months; Breakthrough Therapy designation is possible for the first B7-H3 ADC in SCLC.

H2 2026 (expected)

Xaira Therapeutics — first Big Pharma partnership

The size and quality of the first deal will test how much confidence partners have in Xaira's platform.

This week was about why having a good drug isn't enough. Insurance, channels and partnerships are all waiting after the science. Learning the language of the people who work at those gates is one of the most useful career skills right now. Thanks for reading this week. 🙏

How was this issue?

👍 Loved it 🤔 Could be better

Found this useful? Share it with a classmate. 📤

Share the subscribe link

Follow along → @bio.on_insight

🔗 Sources

① Lilly's oral obesity pill Foundayo off to a slow start amid PBM coverage gaps (Fierce Pharma, Jul 10, 2026) ② GSK × Hansoh ADC risvutatug rezetecan meets survival endpoint in SCLC Phase 3 (Fierce Biotech, Jul 10, 2026) ③ Xaira Therapeutics breaks its silence and seeks Big Pharma partnerships (BioSpace, Jul 8, 2026)

Global biotech & pharma news, translated into career signal —
every Tuesday, for students and early-career professionals.

🌐 Read on the web · past issues archive → bioon-website.vercel.app

The drug works.Now comes the fight over insurance, channels and trust

The drug works.
Now comes the fight over insurance, channels and trust